- Cough, Mucus, and Respiratory Health: A Complete Guide - August 18, 2025
- Flogoprofen: what it's used for and how to take it - June 21, 2025
- What is Movicol oral solution in sachet used for and how to take it? - June 18, 2025
Orphalan, a pioneer in the development of treatments for rare diseases, has launched its drug for Wilson's disease. 'Ke Pei Ou', a treatment based on trientine, is approved by the NMPA (National Medical Products Administration) and becomes the first therapeutic option available in the country for patients with this condition. rare genetic condition.
Strategic alliance to expand access to treatment for Wilson's disease
This launch has been made possible through a strategic partnership with SPH Kyuan Trade, a subsidiary of Shanghai Pharma Group. This collaboration will strengthen Orphalan’s presence in China, ensuring that the treatment reaches the patients who need it most. SPH Kyuan Trade is a leading pharmaceutical distributor in the Chinese market. This allows Orphalan to take its treatment to new heights in this competitive market.
Wilson's disease is a rare genetic disorder that affects the body's ability to eliminate copper. This can lead to severe liver and neurological damage. Ke Pei Ou offers an alternative to penicillamine, a standard treatment that many patients cannot tolerate. Already available in more than 20 countries, the drug now represents new hope for thousands of Chinese patients.
Orphalan strengthens its commitment to the Chinese market.
In addition to the launch of Ke Pei Ou, Orphalan has established a local entity in Shanghai, under the direction of Grace Li, who will lead the company's expansion in China. The strategic focus includes strengthening relationships with healthcare professionals, facilitating medical education and ensuring access to the latest advances in the disease.
Orphalan is not only expanding its presence, but also cementing its reputation as a global leader in orphan drug innovation. Dr. Naseem Amin, CEO of Orphalan, highlighted the importance of this launch, stressing that it is not just about expanding its market, but about improving the quality of life for rare disease patients in China.
This step marks a significant milestone in Orphalan’s global mission, positioning the company as a key player in providing access to innovative treatments and changing the landscape of rare diseases worldwide.
